Former GSK lawyer’s obstruction indictment thrown out, but case may not be over yet
This article was originally published in Scrip
Executive Summary
The attorneys for Lauren Stevens, the former associate general counsel for GlaxoSmithKline who was charged last November with obstructing a US FDA investigation into whether GSK marketed its antidepressant Wellbutrin XL for unapproved use, have convinced a federal judge in Maryland to throw out the indictment. In a 19-page order, Judge Roger Titus of the US District Court for the District of Delaware found that prosecutors gave "erroneous and prejudicial legal advice" when describing her defence to a grand jury. However, Judge Titus ruled that the government can seek a new indictment before a different grand jury.
You may also be interested in...
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Money talks: Verastem leverages IPO to build cancer stem cell pipeline
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.